Orionis and Novartis have expanded an existing deal to develop “molecular glue”, with a new agreement worth up to $1.4 billion, aiming to stick small molecule drugs onto challenging and elusive drug targets.
Tag Archive for: licensing
Swedish biotech AlzeCure Pharma entered a collaboration and licensing agreement with Eli Lilly, granting the biopharma giant global rights to its Alzheimer’s disease candidate Alzstatin (ACD680). Under the terms of the deal, Alzecure will receive $10 million upfront and could receive more than $1 billion in development and commercial milestone payments, in addition to tiered royalties on future sales.
EngitixLondon-based Engitix Ltd has entered a strategic research collaboration and option agreement with GSK to discover and validate new therapeutic targets for liver fibrosis regression, adding another pharma partnership to its extracellular matrix-driven drug discovery platform.
Swiss pharma giant Roche has signed a global licensing and collaboration agreement with US biotech Nurix Therapeutics to co-develop and co-commercialise bexobrutideg, an oral Bruton’s tyrosine kinase (BTK) degrader being developed for B-cell malignancies and potentially for immunology and neurology indications.
French biotech OSE Immunotherapeutics is narrowing its ambitions to just two late-stage programs after a one–two hit: AbbVie backing away from an inflammation partnership and Boehringer Ingelheim halting the liver-disease leg of a separate collaboration following a mid-stage failure. The company now says it will concentrate resources on its cancer vaccine Tedopi and its IL-7 receptor antibody lusvertikimab, while pausing or ending several earlier-stage efforts to conserve cash and push toward near-term clinical catalysts.
Newly formed French biotech Kahimmune Therapeutics has signed an exclusive licensing agreement with Gustave Roussy and SATT Paris-Saclay, securing rights to a technology platform designed to identify tumor antigens derived from the “dark” or non-coding genome. The spin-off, created in late 2025, plans to use the licensed technology to develop shared mRNA cancer vaccines, with an initial program targeting colorectal and pancreatic cancer.
The U.K. biotech Ellipses Pharma, which develops cancer therapeutics, announced a collaboration and licensing agreement with China-based Innolake Biopharm Co. Ltd to develop a clinical-stage, first-in-class antibody–drug conjugate (ADC), EP0028, for solid tumors.
Tay Therapeutics Ltd announces licencing of its oral BET blocker TayB2 to VYNE Therapeutics Inc as a treatment for immuno-inflammatory and fibrotic disorders.